Summary of impact
The Court of Appeal has given employees a clearer path to claiming compensation for inventions that have been of outstanding benefit to their employer. It has done this in two ways. First, it has confirmed that an employee can rely on the combined benefit of several inventions or patents, rather than having to show that one of them is outstanding on its own. Second, it has held that the court must take the parties' financial position into account when it approves costs budgets, which means an employee's exposure to the employer's legal costs can be limited at an early stage.
I don't think this is a reason for employers to be alarmed. Successful claims remain very rare (there have been only two in nearly 50 years), the benefit must still be "outstanding" having regard to the size and nature of the employer's business, and the court must still be satisfied that an award is just. The decision confirms that a body of work can be looked at as a whole, so an employee does not need to point to a single exceptional invention.
Points to note:
• For employers: it is worth knowing which employees have contributed to which inventions, keeping good records of inventorship, and thinking about whether your products rely on a cluster of patents arising from one person's work. A fair internal reward scheme is often the simplest way to recognise that contribution.
• For employee inventors: if your work underpins a significant part of your employer's business, a claim based on several inventions taken together is now a real possibility, and the costs risk of bringing one is more manageable than it was.
The Court of Appeal also said, quite bluntly, that the legislation needs rethinking. That suggests further change may follow, so this is an area to keep an eye on.
_________________________________
The case in brief
Dr David Parsons is an analytical chemist who worked for Convatec, a medical products company focused on advanced wound care, from 1991 to 2023. He says that during that time he devised a number of inventions, now protected by seven patent families, which Convatec has used in products with estimated global sales of around $3.2 billion. He is claiming compensation under section 40 of the Patents Act 1977, and at its highest the claim is valued at about £366 million. Convatec disputes the claim in its entirety.
The claim was started in 2022 and the trial is not due to take place until February 2028 (it is listed for 37 days). The Court of Appeal's decision ([2026] EWCA Civ 1357, handed down on 26 October 2026) was an appeal against two case management rulings made by the Patents Court before trial. It did not decide whether Dr Parsons is entitled to compensation, but it settled two important questions of law:
• whether the court can consider the benefit of more than one invention or patent together when deciding whether the employer has received an "outstanding benefit" (section 40(1)); and
• whether the court must take the employee's financial position into account when approving costs budgets (section 106(1)).
In the Patents Court, Mellor J had declined to decide the first question before trial, and Richards J had held that section 106 did not apply to costs budgeting.
The outcome
The Court of Appeal (Arnold LJ, with whom Asplin LJ and Baker LJ agreed) allowed both of Dr Parsons' appeals.
On the first appeal, the court held that the question of statutory interpretation should have been decided before trial, because it was a pure point of law that did not depend on the facts. It then decided the point in Dr Parsons' favour. The parts of Convatec's Defence asserting that the benefit of multiple inventions or patents cannot be combined were struck out.
On the second appeal, the court held that section 106(1) does apply when approving costs budgets. Richards J had approved future costs of about £6.5 million for Convatec. The Court of Appeal capped Convatec's budgeted costs at £4 million, roughly two-thirds of that figure, having regard to Dr Parsons' modest means and the costs of the after the event (ATE) insurance he would need to cover his exposure.
The substantive claim still has to go to trial, where the judge will decide whether (and which) combinations of inventions and patents it is appropriate to consider together on the facts.
What the decision clarifies
Benefits can be combined (section 40(1))
Convatec argued that each invention or patent had to be of outstanding benefit on its own, and that the Act assumes a one-to-one link between an invention and a patent. The court rejected that argument. It pointed out that the Act itself recognises that one patent may cover several inventions, and that one invention is usually protected by a family of national patents. It also gave several real-world examples where trying to separate out the benefit of each patent would be artificial or unworkable:
• a basic compound patent alongside formulation and dosage patents covering the same product;
• a breakthrough invention which only succeeds commercially because of a later improvement;
• overlapping patents, each of which keeps out a different group of competitors; and
• two alternative solutions, one used by the employer and the other blocking competitors.
The court also agreed that a patent-by-patent approach would allow employers to divide up their protection so that no single patent was ever outstanding.
In practice, this confirms the approach the courts had already taken. In Kelly v GE Healthcare (2009), the first successful section 40 claim, the court assessed the benefit of two patent families together. However, the point had never been argued or decided until now, which is why Convatec was able to challenge it.
Combining benefits is not automatic. Whether it is appropriate in a particular case is a matter for the trial judge to evaluate, and the court noted that the further apart in time the inventions and patents are, the harder it may be to justify relying on their combined benefit. Claimants will also be expected to say clearly, well before trial, which combinations they rely on and why.
Costs protection can apply early (section 106(1))
Section 106(1) requires the court, when deciding whether to award costs and what costs to award, to have regard to all the relevant circumstances, including the financial position of the parties. The court held that this applies to every step on the way to deciding what costs to award, and that approving costs budgets is one of those steps.
This part of the decision is a genuine change in practice. An approved costs budget gives a good indication of what the winning party will recover, and an employee can now ask the court to limit the employer's budgeted costs at the costs management stage, rather than having to wait until the end of the case and hope for relief then. That gives the employee, and anyone insuring or funding the claim, a much clearer view of the risk.
A point of wider interest
Convatec argued that an earlier unreported order by Floyd LJ in Shanks v Unilever bound the court on the section 106 point. The court held that a decision of a single Lord Justice on an application incidental to an appeal is not binding on a later Court of Appeal. That is a useful clarification beyond patent law.
The court's wider comments and what they mean for the future
In a postscript to his judgment, Arnold LJ made some unusually direct remarks about the state of the law. These comments are obiter (they were not needed to decide the appeals), but they carry real weight coming from the Court of Appeal, and from a judge with long experience of patent cases.
He noted that in nearly 50 years there have been just two successful claims under section 40 (Kelly v GE Healthcare and Shanks v Unilever). He said that, even after the 2004 amendments, the legislation is not fit for purpose, that the fundamental problem is that it is too uncertain, and that it needs rethinking. He also observed that other models of employee inventor compensation are available, and earlier in the judgment he referred to the German scheme, which rewards a much larger number of employees.
He was also concerned that this case is taking five and a half years to reach a 37-day trial. He suggested this may be partly due to the size of the claim and the strength of Convatec's opposition, partly due to case management, and he wondered whether costs had already become an obstacle to settlement (the parties have tried mediation three times).
In my view, these comments point to three things to watch:
• Possible reform. The court has, in effect, invited Government and the UK Intellectual Property Office to look again at sections 39 to 43. Any reform could move towards a more predictable system, perhaps along the lines of the German model, but don’t hold your breath waiting for this change, that will take some time.
• Tighter case management. Future section 40 claims can expect the Patents Court to manage them more actively, including early decisions on points of law and clearer definition of the combinations relied on.
• A possible further appeal. Convatec may seek permission to appeal to the Supreme Court, so this may not be the final word on either point.
In the meantime, the decision is binding and it changes the risk picture for both employers and employees. If you would like to talk through what it means for your business or your own inventions, please get in touch.